

VIRTUAL  
FORMAT



*Innovation*  
*in Breast Cancer*  
LISBON EDITION  
*iBC 2023*

**13 · 14**

**November 2023**

(WET) Western European Time

DIRECTOR

Luís Costa

Hospital de Santa Maria, Lisbon, Portugal

CO-DIRECTOR

Miguel Martín

Hospital General Universitario Gregorio Marañón, Madrid, Spain

[www.innovationinbreastcancer.com/lisbon](http://www.innovationinbreastcancer.com/lisbon)

15:00 - 15:15

**Introduction**

Luís Costa, Hospital de Santa Maria, Lisbon, Portugal

15:15 - 16:25

**SESSION I HIGH-RISK EARLY BREAST CANCER**

Chair:

Luís Costa, Hospital de Santa Maria, Lisbon, Portugal

15:15 - 15:35

**Surgery after neoadjuvant treatment:  
How does clinical stage determine the options?**

Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, USA

15:35 - 15:55

**(Neo) Adjuvant medical treatment in triple-negative breast cancer**

Peter Schmid, Barts Breast Cancer Centre, London, UK

15:55 - 16:05

**Local relapse: Time to revisit treatment options?**

Michael Gnant, Medical University of Vienna, Austria

16:05 - 16:25

**Discussion**

16:25 - 16:40

**Break**

16:40 - 18:00

**SESSION II RISING OPTIONS FOR LUMINAL BREAST CANCER**

Chair:

Miguel Abreu, Instituto Português de Oncologia do Porto, Portugal

16:40 - 17:00

**Metastatic relapse during adjuvant hormonal treatment – Main options**

Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA

17:00 - 17:20

**ADCs in metastatic luminal breast cancer**

Aditya Bardia, Harvard Medical School, Boston, USA

17:20 - 17:40

**Endocrine adjuvant therapy in pre-menopause**

Eva Ciruelos, Hospital 12 de Octubre, Madrid, Spain

17:40 - 18:00

**Discussion**

15:00 - 15:05 **Opening remarks for the day**  
Luís Costa, Hospital de Santa Maria, Lisbon, Portugal

**15:05 - 16:35 SESSION III CHALLENGING TOPICS**

Chair: Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain  
Rita Teixeira de Sousa, Hospital de Santa Maria, Lisbon, Portugal

15:05 - 15:25 **Improving survival in patients with brain metastases**  
Nancy Lin, Harvard Medical School, Boston, USA

15:25 - 15:45 **First-line in extensive visceral disease in triple-negative breast cancer**  
Mafalda Oliveira, Hospital Universitario Vall d'Hebron, Barcelona, Spain

15:45 - 16:05 **Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy**  
Marion van Mackelenbergh, University Hospital Schleswig-Holstein, Kiel, Germany

16:05 - 16:35 **Discussion**

16:35 - 16:50 **Break**

**16:50 - 17:30 KEYNOTE LECTURE**

Chair: Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain

16:50 - 17:20 **Translational chemical biology**  
Gonçalo Bernardes, University of Cambridge, UK

17:20 - 17:30 **Discussion**

**17:30 - 19:00 SESSION IV FILLING THE SPOT WITH ACADEMIC AND TRANSLATIONAL RESEARCH**

Chair: Luís Costa, Hospital de Santa Maria, Lisbon, Portugal

17:30 - 17:50 **Solving questions through academic clinical research**  
Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain

17:50 - 18:10 **Predicting response to neoadjuvant therapy in local-regional HER2-positive breast cancer**  
Tomás Pascual, Hospital Clínic de Barcelona, Spain

18:10 - 18:30 **Discussion**

18:30 **Closing remarks**

## Sponsors

### Platinum



### Gold



### Silver



### Bronze



### Other collaborations



## Under the auspices of



UNIVERSIDADE  
DE LISBOA



## Organized by



Tel.: (+351) 912 950 061  
e-mail: [ibc-lisbon@doctaforum.com](mailto:ibc-lisbon@doctaforum.com)  
[www.innovationinbreastcancer.com/lisbon](http://www.innovationinbreastcancer.com/lisbon)